Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target.
Tyra Biosciences Inc. (TYRA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 12,198,625 | $467,207,338 | 4.95% | |
| 2. | Farallon Capital Thomas Steyer | 3,580,818 | $137,145,329 | +74% | 0.78% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,475,000 | $94,792,500 | -27% | 5.48% |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 2,054,991 | $78,706,155 | 1.61% | |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,976,196 | $75,688,307 | -8% | 2.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 11,813 | $119,665.69 | 10,259,291 | 2025-06-16 | Filing | |
| $10.20 | 120,167 | $1,225,703.40 | 10,247,478 | 2025-06-13 | Filing | |
| $10.20 | 31,307 | $319,331.40 | 10,127,311 | 2025-06-12 | Filing | |
| $10.19 | 186,850 | $1,904,001.50 | 10,096,004 | 2025-06-09 | Filing | |
| $10.04 | 213,334 | $2,141,873.36 | 9,909,154 | 2025-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.97 | 14,295 | $528,506.16 | 28,231 | 2026-03-25 | Filing | |
| $33.37 | 5,872 | $195,928.68 | 146,981 | 2026-02-12 | Filing | |
| $31.50 | 2,128 | $67,035.83 | 152,853 | 2026-02-12 | Filing | |
| $29.08 | 1,017 | $29,575.17 | 154,981 | 2026-01-12 | Filing | |
| $28.44 | 6,983 | $198,610.49 | 155,998 | 2026-01-12 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,823,425 | $122,120,195 | 95.92% | |
| 2. | 750,000 | $23,955,000 | 18.82% | |
| 3. | 29,519 | $942,837 | 0.03% | |
| 4. | 21,020 | $671,379 | 0.19% | |
| 5. | 10,850 | $346,549 | 0% |
News See All
10 Most Promising Cancer Stocks According to Wall Street Analysts
Regardless of the state of the economy, the pharmaceutical business has continued to be one of the healthcare market's most robust sectors thanks to the consistent need for medications, vaccinations, ...
10 Best Russell 2000 Stocks to Invest In According to Hedge Funds
On May 29, Reuters reported that the Russell 2000 fell 0.6%, lagging the broader Wall Street indexes, which closed at new highs.
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA with a Buy rating and set a price target of $54.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
Oppenheimer's Favorite Stocks For Next 12 Months: Top 32 Stock Picks
The tail end of August is appearing to turn a fresh page for Wall Street.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
Hedge Fund Resource Center